These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10553211)

  • 41. FDA policy on unapproved drug products: past, present, and future.
    Chhabra R; Kremzner ME; Kiliany BJ
    Ann Pharmacother; 2005; 39(7-8):1260-4. PubMed ID: 15956239
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sandoz sues FDA over delay in first biogeneric approval.
    Fox JL
    Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046
    [No Abstract]   [Full Text] [Related]  

  • 43. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Foreign Establishment Registration and United States agent requirements.
    Nolte CJ; McNamara-Cullinane M
    Med Device Technol; 2002 Dec; 13(10):32-3. PubMed ID: 12575528
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Satisfying the requirements of the Food and Drug Administration and Centers for Medicare and Medicare Services.
    Smith JJ; Henderson JA
    J Am Coll Radiol; 2008 Mar; 5(3):189-92. PubMed ID: 18312966
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What are biologics? A comparative legislative, regulatory and scientific analysis.
    Korwek EL
    Food Drug Law J; 2007; 62(2):257-304. PubMed ID: 17632962
    [No Abstract]   [Full Text] [Related]  

  • 47. Prospects for application of biotechnology-derived biomaterials.
    Hellman KB; Picciolo GL; Fox CF
    J Cell Biochem; 1994 Oct; 56(2):210-24. PubMed ID: 7829583
    [No Abstract]   [Full Text] [Related]  

  • 48. Human-nonhuman chimeras: a regulatory proposal on the blurring of species lines.
    Kopinksi NE
    Boston Coll Law Rev; 2004 May; 45(3):619-66. PubMed ID: 16514749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products.
    Kruhlak NL; Contrera JF; Benz RD; Matthews EJ
    Adv Drug Deliv Rev; 2007 Jan; 59(1):43-55. PubMed ID: 17229485
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FDA reform: activists' proposals. Food and Drug Administration.
    James JS
    AIDS Treat News; 1995 Aug; (no 228):6-8. PubMed ID: 11362628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Legal and ethical issues in the regulation and development of engineering achievements in medical technology: a 2006 perspective.
    Malloy A
    Conf Proc IEEE Eng Med Biol Soc; 2006; Suppl():6660-2. PubMed ID: 17959479
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Refining the qualification process for medical materials.
    Brodhagen TW
    Med Des Mater; 1991 Jan; 1(1):26-31. PubMed ID: 10147989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regulatory aspects of total product life cycle.
    Hausman ED; Altaie SS
    Diabetes Technol Ther; 2004 Dec; 6(6):761-6. PubMed ID: 15684626
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Products liability relating to biotechnology--an overview.
    Simpson J; Jaques MS
    Australas Biotechnol; 1992 Feb; 2(1):32-5. PubMed ID: 1368029
    [No Abstract]   [Full Text] [Related]  

  • 55. Authority of the Food and Drug Administration to require data access and control use rights in the Sentinel data network.
    Evans BJ
    Food Drug Law J; 2010; 65(1):67-112, ii. PubMed ID: 24475535
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Introduction to the issues: appropriate methods of process validation.
    Scribner CL
    Dev Biol Stand; 1992; 76():213-4. PubMed ID: 1478338
    [No Abstract]   [Full Text] [Related]  

  • 57. The FDA "reinvents" human cell and tissue regulations.
    Brower V
    Nat Biotechnol; 1997 May; 15(5):411. PubMed ID: 9131612
    [No Abstract]   [Full Text] [Related]  

  • 58. FDA regulation of biomedical software.
    Gamerman GE
    Proc Annu Symp Comput Appl Med Care; 1992; ():745-9. PubMed ID: 1482971
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Some legal implications in biotechnology.
    Hannah HW
    J Am Vet Med Assoc; 1992 Jun; 200(11):1634-5. PubMed ID: 1624337
    [No Abstract]   [Full Text] [Related]  

  • 60. FDA raps liquid biopsy firm.
    Nat Biotechnol; 2015 Nov; 33(11):1117. PubMed ID: 26544123
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.